Credit Suisse’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-51,931
| Closed | -$2M | – | 3206 |
|
|
2023
Q2 | $2M | Buy |
51,931
+17,680
| +52% | +$454K | ﹤0.01% | 1912 |
|
|
2023
Q1 | $793K | Buy |
34,251
+2,074
| +6% | +$49.4K | ﹤0.01% | 2463 |
|
|
2022
Q4 | $843K | Buy |
32,177
+2,624
| +9% | +$58.1K | ﹤0.01% | 2459 |
|
|
2022
Q3 | $581K | Buy |
29,553
+2,821
| +11% | +$56.6K | ﹤0.01% | 2701 |
|
|
2022
Q2 | $467K | Buy |
+26,732
| New | +$420K | ﹤0.01% | 2886 |
|
|
2020
Q1 | – | Sell |
-2,328
| Closed | -$14K | – | 4316 |
|
|
2019
Q4 | $14K | Sell |
2,328
-3,210
| -58% | -$17.4K | ﹤0.01% | 4127 |
|
|
2019
Q3 | $29K | Buy |
5,538
+713
| +15% | +$4.73K | ﹤0.01% | 4073 |
|
|
2019
Q2 | $37K | Buy |
4,825
+82
| +2% | +$1.25K | ﹤0.01% | 4018 |
|
|
2019
Q1 | $94K | Buy |
4,743
+795
| +20% | +$13.9K | ﹤0.01% | 3853 |
|
|
2018
Q4 | $52K | Sell |
3,948
-5,635
| -59% | -$113K | ﹤0.01% | 3798 |
|
|
2018
Q3 | $352K | Buy |
9,583
+3,379
| +54% | +$108K | ﹤0.01% | 3458 |
|
|
2018
Q2 | $217K | Buy |
6,204
+1,518
| +32% | +$58.2K | ﹤0.01% | 3741 |
|
|
2018
Q1 | $218K | Buy |
4,686
+490
| +12% | +$17.9K | ﹤0.01% | 3682 |
|
|
2017
Q4 | $157K | Sell |
4,196
-3,502
| -45% | -$153K | ﹤0.01% | 3790 |
|
|
2017
Q3 | $409K | Buy |
7,698
+4,732
| +160% | +$281K | ﹤0.01% | 3598 |
|
|
2017
Q2 | $169K | Sell |
2,966
-1,451
| -33% | -$72.8K | ﹤0.01% | 3653 |
|
|
2017
Q1 | $237K | Sell |
4,417
-1,169
| -21% | -$66K | ﹤0.01% | 3587 |
|
|
2016
Q4 | $318K | Sell |
5,586
-1,097
| -16% | -$66.4K | ﹤0.01% | 3635 |
|
|
2016
Q3 | $415K | Sell |
6,683
-506
| -7% | -$35.8K | ﹤0.01% | 3520 |
|
|
2016
Q2 | $406K | Sell |
7,189
-3,348
| -32% | -$203K | ﹤0.01% | 3543 |
|
|
2016
Q1 | $676K | Buy |
10,537
+5,474
| +108% | +$443K | ﹤0.01% | 3016 |
|
|
2015
Q4 | $712K | Buy |
+5,063
| New | +$688K | ﹤0.01% | 3105 |
|
Credit Suisse's KDNY Position: Q3 2023 in Review
Credit Suisse sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 51,931 shares — an estimated $2M sold.
Credit Suisse first reported a position in KDNY in Q4 2015 and held it in 22 quarters. The position peaked at $2M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Credit Suisse reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Credit Suisse sold 51,931 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $2M.
- Credit Suisse first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 22 quarters.
- Credit Suisse's Chinook Therapeutics, Inc. Common Stock position peaked at $2M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Credit Suisse's 13F filing for Q3 2023, filed 13 Nov 2023.